Meridian Bioscience (VIVO) Tops Q2 EPS by 35c

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.67, $0.35 better than the analyst estimate of $0.32. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $83.29 million.

GUIDANCE:

Meridian Bioscience sees FY2022 EPS of $1.30-$1.40, versus the consensus of $1.37. Meridian Bioscience sees FY2022 revenue of $330-345 million, versus the consensus of $337 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance